Kenvue Inc. (NYSE:KVUE) Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp boosted its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 20,069,238 shares of the company's stock after acquiring an additional 518,988 shares during the quarter. Van ECK Associates Corp owned about 1.05% of Kenvue worth $428,478,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Grove Bank & Trust increased its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Riverview Trust Co acquired a new position in Kenvue in the third quarter valued at approximately $30,000. Geneos Wealth Management Inc. acquired a new position in Kenvue in the fourth quarter valued at approximately $29,000. Ashton Thomas Securities LLC purchased a new stake in Kenvue in the third quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC raised its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.49 on Friday, hitting $21.94. The company had a trading volume of 27,015,716 shares, compared to its average volume of 13,018,513. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The stock has a 50 day moving average price of $21.32 and a 200 day moving average price of $22.07. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $42.07 billion, a price-to-earnings ratio of 41.40, a P/E/G ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts expect that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.74%. The ex-dividend date is Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Analysts Set New Price Targets

KVUE has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a "buy" rating to a "hold" rating and decreased their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Finally, Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.